title: [Dapoxetine for premature ejaculation: Advances in clinical studies].
abstract: Premature ejaculation (PE) is a most common sexual dysfunction, for which dapoxetine, a novel selective serotonin (5-HT) re-uptake inhibitor (SSRI), is the only licensed oral medicine at present. With the advantages of fast absorption, rapid action, on-demand medication, and short half-life time, dapoxetine has been proved by clinical trials to be effective in prolonging the intravaginal ejaculation latency time (IELT) and improving the overall condition of PE patients in various areas and populations. Compared with the traditional SSRIs, dapoxetine has a better safety and tolerability. The most frequently reported dapoxetine-related adverse events include nausea, diarrhea, headache and dizziness, but with very few severe or serious cases.
authors.forename: Ting-you
authors.initials: TY
authors.lastname: Zhou
authors.forename: Yan-feng
authors.initials: YF
authors.lastname: Li
mesh_terms: D001596:Benzylamines / Q000627:therapeutic use*; D035843:Biomedical Research; D004542:Ejaculation / Q000187:drug effects*; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D061686:Premature Ejaculation / Q000188:drug therapy*; D011930:Reaction Time / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001596:Benzylamines; D009281:Naphthalenes; D017367:Selective Serotonin Reuptake Inhibitors; C080598:dapoxetine